Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) was up 4% on Tuesday . The stock traded as high as $41.60 and last traded at $41.05, with a volume of 353,892 shares. The stock had previously closed at $39.49.

Several equities research analysts have recently weighed in on PCRX shares. Wedbush reiterated an “outperform” rating and set a $113.00 price objective on shares of Pacira Pharmaceuticals in a research report on Wednesday, May 4th. Mizuho reissued a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, May 26th. BMO Capital Markets assumed coverage on shares of Pacira Pharmaceuticals in a research note on Tuesday, June 28th. They set an “underperform” rating and a $36.00 target price on the stock. Brean Capital lowered shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 1st. Finally, Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a research note on Tuesday, July 26th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $73.64.

The stock’s market capitalization is $1.48 billion. The company’s 50 day moving average is $40.19 and its 200 day moving average is $47.09.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Thursday, August 4th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.03 by $0.16. The firm earned $69.60 million during the quarter, compared to analysts’ expectations of $67.80 million. The firm’s quarterly revenue was up 17.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.20 earnings per share. Analysts expect that Pacira Pharmaceuticals Inc. will post $0.42 EPS for the current year.

In other Pacira Pharmaceuticals news, VP Lauren Bullaro Riker sold 938 shares of the business’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $47.66, for a total transaction of $44,705.08. Following the transaction, the vice president now directly owns 5,945 shares of the company’s stock, valued at approximately $283,338.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, President James S. Scibetta sold 25,000 shares of the business’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $45.21, for a total transaction of $1,130,250.00. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Pacira Pharmaceuticals stock. KBC Group NV increased its position in shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) by 2,685.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,024 shares of the company’s stock after buying an additional 27,018 shares during the period. KBC Group NV owned about 0.08% of Pacira Pharmaceuticals worth $2,152,000 as of its most recent filing with the SEC.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.